Welcome to our dedicated page for CEL-SCI news (Ticker: CVM), a resource for investors and traders seeking the latest updates and insights on CEL-SCI stock.
CEL-SCI Corporation develops cancer immunotherapy programs centered on Multikine (Leukocyte Interleukin, Injection), an investigational neoadjuvant therapy for squamous cell carcinoma of the head and neck. Company news commonly covers Multikine regulatory interactions, FDA Orphan Drug designation for neoadjuvant use, confirmatory registration-study preparation, and the company's positioning of the therapy before surgery, radiation, and chemotherapy.
Updates also include financial results, public equity offerings used to fund Multikine development, investor presentations, and regional commercialization or regulatory-affairs agreements, including activity in Saudi Arabia. CEL-SCI's disclosures often connect clinical development with working-capital needs and potential international market access.
CEL-SCI (NYSE American:CVM) reported fiscal Q2 2026 results and key updates on Multikine. The company is preparing a 212-patient U.S. FDA Confirmatory Registration Study in head and neck cancer, targeting start by summer/fall 2026.
CEL-SCI signed a 50%/50% revenue-sharing partnership with Amarox/b) for Multikine in Saudi Arabia, tied to potential SFDA Breakthrough Medicine Designation, and raised approximately
CEL-SCI (NYSE American: CVM) closed a best-efforts public offering of 6,000,000 common shares at $1.20 per share, generating approximately $7.2 million in gross proceeds.
According to CEL-SCI, net proceeds will fund continued development of Multikine, as well as general corporate purposes and working capital.
CEL-SCI (NYSE American:CVM) priced a best-efforts public offering of 6,000,000 common shares at $1.20 per share, targeting gross proceeds of about $7.2 million. Closing is expected on May 13, 2026, with proceeds funding Multikine development, general corporate purposes, and working capital. ThinkEquity is sole placement agent.
CEL-SCI (NYSE American:CVM) signed a strategic partnership with Amarox for registration, commercialization, and distribution of Multikine for head and neck cancer in Saudi Arabia, with optional GCC expansion.
The agreement includes a 50%/50% net revenue split in Saudi Arabia and exclusive distribution for Amarox upon SFDA approval, targeting SFDA Breakthrough Medicine Designation aligned with Saudi Vision 2030.
CEL-SCI (NYSE American: CVM) reported Q1 FY2026 results and clinical progress for Multikine in head and neck cancer. The company plans to begin enrollment in a 212-patient U.S. confirmatory registration study in summer 2026 and has submitted a Breakthrough Medicine Designation application to the Saudi FDA.
Q1 operating highlights: R&D $3.7M, G&A $1.7M, net loss $5.5M, cash used in operations $4.0M. Prior Phase 3 showed 5-year overall survival 73% vs 45%.
CEL-SCI (NYSE American: CVM) reported fiscal 2025 results and clinical progress for Multikine in head and neck cancer. The company received FDA clearance to proceed with a 212-patient Confirmatory Registration Study with enrollment expected to begin in Spring 2026 and plans to seek early U.S. approval based on pre-surgical response data by 2028. CEL-SCI filed for Breakthrough Medicine Designation in Saudi Arabia and completed manufacturing of Multikine doses for the confirmatory study at its validated U.S. cGMP facility. Fiscal 2025 highlights: R&D $15.9M (-13%), Net loss $25.4M, Operating cash expenditures $17.1M, and Gross proceeds raised $28.3M. The audited financials include an explanatory going concern paragraph.
CEL-SCI (NYSE American: CVM) will present at the LD Micro "Main Event" investor conference on October 21, 2025 at 9:30 a.m. PST. Geert Kersten, Chief Executive Officer, will deliver a 20-minute virtual corporate presentation outlining the company's strategic roadmap for continued development of Multikine. Investors can register to watch the live webcast at the LD Micro registration page.
CEL-SCI (NYSE American: CVM) announced that CEO Geert Kersten will present at the LD Micro "Main Event" investor conference on October 21, 2025 at 9:30 a.m. PST.
The conference runs October 19–21, 2025 at the Hotel Del Coronado in San Diego. Kersten will deliver a 20-minute corporate presentation outlining the company's strategic roadmap for the continued development of Multikine and will be available for one-on-one investor meetings during the event.
CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, has successfully closed a $10 million public offering of 1,111,200 common stock shares at $9.00 per share.
The offering was conducted under a shelf registration statement and managed by ThinkEquity as the sole placement agent. The company plans to use the proceeds to fund the development of Multikine, their investigational cancer therapy that has received FDA Orphan Drug designation for neoadjuvant therapy in head and neck squamous cell carcinoma patients. Multikine has been administered to over 740 patients and is designed to boost patients' immune systems before conventional cancer treatments.
CEL-SCI Corporation (NYSE American: CVM) has announced the pricing of a public offering of 1,111,200 shares of common stock at $9.00 per share, aiming to raise approximately $10 million in gross proceeds. The offering, expected to close on August 29, 2025, is being conducted through ThinkEquity as the sole placement agent.
The company plans to use the proceeds to fund the continued development of Multikine, their investigational cancer immunotherapy treatment that has received FDA Orphan Drug designation for neoadjuvant therapy in head and neck squamous cell carcinoma patients. Multikine has been administered to over 740 patients and is designed to boost patients' immune systems before conventional cancer treatments begin.